- Active not recruitingPHASE3
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
This study compares two medicines, X-396 (ensartinib) and crizotinib, for people with a specific type of lung cancer called ALK-positive non-small cell lung cancer. It looks at how well each medicine works and if they are safe.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
For: Metastatic Uveal MelanomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
This study compares two drugs, lorlatinib and crizotinib, for people with a specific type of advanced lung cancer called ALK-positive NSCLC. It aims to see if lorlatinib works better at stopping the cancer from growing for longer. This is for patients who haven't had previous treatment for their advanced cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia